

Confirmation  
of the final results of the MabionCD20 NHL clinical trial

In  
reference to Current Report No. 6/2018 dated 15 January 2018 and  
subsequent current reports regarding initial results of the MabionCD20  
clinical trial carried out on patients treated for non-Hodgkin's  
lymphomas \_NHL\_, the Management Board of Mabion S.A. \_The "Company"\_  
hereby informs that on May 25, 2018 an external entity contracted to  
analyse the results regarding responses to treatment of RA patients  
provided it with a confirmation that the status of results of the  
clinical trial reported in the aforementioned reports, after a detailed  
verification, has been changed from "initial" to "final".

Hence  
the positive assessment of results of the clinical trial remained  
unchanged.

The  
final versions of reports will be attached to the marketing  
authorisation application \_MAA\_. The Company notes that positive results  
of the trial do not guarantee that the product will be approved by the  
European Medicines Agency \_EMA\_.